Severe anemia in patients with Propionic acidemia is associated with branched-chain amino acid imbalance

Sinziana Stanescu1*, Amaya Belanger-Quintana1, Borja Manuel Fernandez-Felix2, Francisco Arrieta3, Victor Quintero4, Maria Soledad Maldonado4, Patricia Alcaide5 and Mercedes Martínez-Pardo1

Abstract

Background: Propionic acidemia (PA), an inborn error of metabolism, is caused by a deficiency in propionyl-CoA carboxylase. Patients have to follow a diet restricted in the propiogenic amino acids isoleucine (Ile), valine (Val), methionine (Met) and threonine (Thr); proper adherence can prevent and treat acute decompensation and increase life expectancy. However, chronic complications occur in several organs even though metabolic control may be largely maintained. Bone marrow aplasia and anemia are among the more common.

Materials and methods: In this retrospective study, data for patients with PA being monitored at the Hospital Ramón y Cajal (Madrid, Spain) (n = 10) in the past 10 years were examined to statistically detect relationships between persistent severe anemia outside of metabolic decompensation episodes and dietary practices such as natural protein intake and medical food consumption (special mixture of precursor-free amino acids) along with plasma levels of branched-chain amino acids (BCAA). High ferritin levels were deemed to indicate that a patient had received repeated transfusions for persistent anemia since data on hemoglobin levels at the moment of transfusion were not always passed on by the attending centers.

Results: Three patients had severe, persistent anemia that required repeated blood transfusions. Higher medical food consumption and plasma Leu levels were associated with iron overload. Notably, natural protein intake and plasma Val were negatively correlated with ferritin levels. We also observed an inverse relationship between plasma Val/Leu and Ile/Leu ratios and ferritin.

Conclusion: The present results suggest that severe anemia in patients with PA might be associated with low natural protein intake and BCAA imbalance.

Keywords: Propionic acidemia, Anemia, Diet, Protein-restricted, Branched-chain amino acids imbalance

Background

Propionic acidemia (PA; OMIM 606054) is a rare, inherited (autosomic recessive) metabolic disease caused by a deficiency in propionyl-CoA carboxylase, a mitochondrial enzyme that transforms propionyl-CoA into methylmalonyl-CoA. Propionyl-CoA is an intermediate in the metabolism of the amino acids isoleucine (Ile), valine (Val), methionine (Met) and threonine (Thr). Other sources of propionyl-CoA include odd-numbered long-chain fatty acids (OLCFAs), cholesterol, and propionic acid generated by gut bacteria. Propionyl-CoA deficiency leads to the accumulation of 3-hydroxy propionic acid and methyl citrate, propionyl carnitine and tiglyl

*Correspondence: sinziana.stanescu@salud.madrid.org
1 Servicio de Pediatría, Unidad de Enfermedades Metabólicas, Hospital Universitario Ramón y Cajal, IRYCIS, Ctra de Colmenar Viejo, km 9,100, 28034 Madrid, Spain
Full list of author information is available at the end of the article

© The Author(s) 2021. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
glycine among other abnormal intermediates of propionyl-CoA metabolism [1].

Commonly beginning in neonatal life, patients with PA experience acute metabolic decompensation during scenarios involving increased catabolism, e.g., infections or prolonged fasting. These episodes are the result of intoxication by alternative metabolism products, leading to lactic acidosis, ketosis, hyperammonemia, and multiorgan failure [2]. Moreover, patients with PA, even those with good metabolic control, suffer chronic complications involving organs with high energy demands, e.g., the central nervous system (encephalopathy, abnormal movements, epilepsy, psychomotor delay, ataxia, lesions in the basal ganglia similar to those seen in Leigh's syndrome, and atrophy of the optic nerve), the heart (dilated cardiomyopathy, arrhythmias), bone marrow (bone marrow aplasia, cytopenia), and the gastrointestinal tract (pancreatitis, hepatitis), etc [3]. No complete pathophysiological explanation for this is yet available. Treatment is based largely on dietary natural protein restriction to limit the intake of amino acids providing precursors of propionyl-CoA (Met, Thr, Val and Ile), together with a special mixture of precursor-free amino acids (SMAA) when the natural protein tolerance is below FAO/WHO/UNU (2007) recommendations, plus the administration of carnitine and metronidazole [2, 4].

The main aim of the present work was to detect the possible relationships between severe anemia in patients with PA outside of metabolic decompensation episodes and nutritional parameters, such as protein intake and BCAA plasma levels.

Materials and methods

The medical records of patients with PA being monitored in the past 10 years at the Metabolic Disease Unit, Hospital de Ramón y Cajal (Madrid, Spain) (N = 10), were examined in order to identify those with significant anemia outside of metabolic decompensation episodes. Since these patients receive periodic transfusions of blood derivatives at hospitals other than the above, high plasma ferritin was used as a marker of iron overload secondary to repeated transfusions for severe anemia. This proxy was employed since hemoglobin levels at the moment of reference were normal (see Additional file 2), but without benefit. Median natural protein prescription was below the WHO/FAO/UNU (2007) safe levels, therefore SMAA supplements was prescribed for all the patients included (see Table 2). All received treatment with metronidazole, carnitine and Ile supplements; the caloric intake was maintained between 100 and 150 kcal/kg/day.

The natural protein intake (g/kg/day) was negatively associated with iron overload (p-value 0.003, regression coefficient (95% C.I): -72.1 (-119.6; -24.5)), whereas the SMAA consumption (g/kg/day) resulted in higher plasma ferritin levels (p-value 0.019, regression coefficient (95% C.I): 37.8 (6.1; 69.5)). Notably, the
hyperferritinemia was associated with lower levels of Val (p-value < 0.001, regression coefficient (95% C.I): \(-8.6 \text{ (−12.3; −4.8)}\)) and higher levels of Leu (p-value 0.001, regression coefficient (95% C.I): \(5.6 \text{ (2.2; 9.1)}\), see Fig. 1 and Table 3. Also, a negative correlation was observed between the ratios of Val/Leu (p-value < 0.001, regression coefficient (95% C.I): \(-771.5 \text{ (−987.4; −555.5)}\)) and Ile/Leu (p-value < 0.018, regression coefficient (95% C.I): \(-431 \text{ (−788.6; −73.3)}\)) with the ferritin suggesting that BCAA imbalance was potentially detrimental for the bone marrow, see Fig. 1 and Table 3.

**Discussion**

The long-term complications suffered by patients with PA affects their prognosis [3]. Certainly, they increase morbidity and mortality rates outside of the acute decompensation episodes. Given the small number of patients with PA, the actual prevalence of hematological

**Table 1** Demographic and clinical data of 10 PA patients included in the study

| Sex | Current age (years) | Age at diagnosis | Genetics | Clinical course (long term complications) |
|-----|---------------------|------------------|----------|-------------------------------------------|
| 1 F | 32                  | Neonatal         | PCCB gene p.Gly407Argfs*14/p.Arg165Gln | Peripheric neuropathy, neuromotor delay, pancreatitis, thrombopenia Severe persistent anemia |
| 2 M | 12                  | Neonatal         | PCCB gene p.Gly407Argfs*14/ p.Arg410Trp | Severe neuromotor delay, leukopenia Severe persistent anemia |
| 3 M | Died (5)            | Neonatal         | PCCA gene p.Leu470Arg/p.Leu470Arg | Severe neuromotor delay Choreaathetosis, basal ganglia involvement, leukopenia, frequent infections, dilated cardiomyopathy, pancreatitis Severe persistent anemia |
| 4 F | 15                  | 4 months         | PCCA gene p.Gly477fs*9/p.Cys616_Val633del | Pancreatitis |
| 5 M | 9                   | Neonatal screening | PCCB p.Asn536Asp/p.Asn536Asp | Autism |
| 6 F | 27                  | 4 months         | PCCB gene p.Gly407Argfs*14/p.Glu168Lys | – |
| 7 M | 12                  | 6 months         | PCCA gene p.Gly477fs*9/p.Cys616_Val633del | Severe neuromotor delay |
| 8 F | 13                  | 6 months         | PCCB gene p.Arg512Cys/p.Gly255Ser | Neuroromotor delay, epilepsy, pancreatitis, myositis |
| 9 F | 38                  | Neonatal         | PCCB p.Glu168Lys/p.7 (c.183 + 3G > C) | Neuroromotor delay |
| 1 F | 32                  | Neonatal         | PCCB gene p.Gly407Argfs*14/p.Gly407Argfs*14 | Neuroromotor delay, dilated cardiomyopathy |

**Table 2** Descriptive statistics for ferritin levels and nutritional support: natural protein intake (NPI) (g/kg/day), special mixture of precursor-free amino acids (SMAA) intake (g/kg/day), total protein intake, % of protein provided by natural protein intake

| Patient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 |
|---------|---|---|---|---|---|---|---|---|---|----|
| Measures (N) | N = 10 | N = 24 | N = 9 | N = 4 | N = 12 | N = 5 | N = 9 | N = 3 | N = 3 | N = 7 |
| **Natural protein intake (NPI) (g/kg/day)** | | | | | | | | | | |
| Mean (sd) | 0.29 (0.14) | 0.55 (0.25) | 0.79 (0.29) | 0.58 (0.06) | 0.96 (0.07) | 0.39 (0.01) | 0.72 (0.06) | 0.24 (0.00) | 0.32 (0.09) | 0.28 (0.09) |
| Min; max | 0.11; 0.46 | 0.17; 0.89 | 0.4; 1.2 | 0.5; 0.65 | 0.87; 1.1 | 0.38; 0.41 | 0.6; 0.3 | 0.24; 0.24 | 0.21; 0.36 | 0.16; 0.36 |
| **SMAA intake (g/kg/day)** | | | | | | | | | | |
| Mean (sd) | 1.23 (0.23) | 1.97 (0.33) | 1.58 (0.2) | 1.41 (0.2) | 2 (0.2) | 0.62 (0.02) | 2.3 (0.13) | 1.7 (0.00) | 0.96 (0.09) | 1.0 (0.00) |
| Min; max | 0.92; 1.5 | 1.61; 2.77 | 1.33; 1.93 | 1.2; 1.66 | 1.86; 2.15 | 0.61; 0.66 | 2.1; 2.5 | 1.7; 1.7 | 0.91; 1.07 | 1.0; 1.0 |
| **Amount of total protein from natural protein (%)** | | | | | | | | | | |
| Mean (sd) | 19.1 (8.5) | 22 (9.5) | 33 (10) | 29.5 (4.9) | 35.5 (1.8) | 38.5 (0.00) | 24 (1.9) | 12 (0.00) | 25 (7) | 21.5 (5.8) |
| Min; max | 7.2; 28.5 | 7.4; 35 | 17.44 | 23; 33.3 | 30; 36 | 38.5; 38.5 | 19.26 | 12; 12 | 16.6; 29 | 14; 26 |
| **Ferritin (ng/ml); NV. 20–250 ng/ml** | | | | | | | | | | |
| Mean (sd) | 429.1 (223.6) | 873.1 (768.1) | 556.2 (657.2) | 56 (28.3) | 24.6 (11.2) | 34.4 (6.6) | 76 (39) | 25 (23) | 728 (27.3) | 245 (186) |
| Min; max | 124; 829 | 142; 2926 | 103; 2085 | 24; 93 | 9.5 | 28; 44 | 25; 139 | 10; 53 | 51; 103 | 111; 651 |

hypoferritinemia was associated with lower levels of Val (p-value < 0.001, regression coefficient (95% C.I): –8.6 (−12.3; −4.8)) and higher levels of Leu (p-value 0.001, regression coefficient (95% C.I): 5.6 (2.2; 9.1), see Fig. 1 and Table 3. Also, a negative correlation was observed between the ratios of Val/Leu (p-value < 0.001, regression coefficient (95% C.I): −771.5 (−987.4; −555.5)) and Ile/Leu (p-value < 0.018, regression coefficient (95% C.I): −431 (−788.6; −73.3)) with the ferritin suggesting that BCAA imbalance was potentially detrimental for the bone marrow, see Fig. 1 and Table 3.
complications is unknown. A recent meta-analysis determined anemia to be more common than cardiomyopathy or lesions in the basal ganglia [3]. In another study of the long-term complications of organic acidemia and urea cycle disorders (as recorded in the European Registry of Organic Acidemia and Urea Cycle Disorders), the prevalence of anemia among patients with PA was determined to be 22%, while figures for leucopenia and thrombocytopenia reached 18% [6]. Pancytopenia has generally been described as occurring during periods of acute decompensation, but patients can also experience anemia, neutropenia or thrombocytopenia outside of these times [2]. The reason for these hematological problems may lie in the toxicity of accumulating metabolites such as 3-hydroxy propionic acid, methyl citrate or tiglyl glycine, a lack of certain nutrients [6], or mitochondrial dysfunction [3]. The pancytopenia seen during decompensation episodes is generally reversible [2, 7, 8], supporting the idea that accumulating toxic metabolites are to blame. However, why hematological problems should occur during times of metabolic stability remains unclear.

The blood is a tissue with a high regeneration rate. The need for nutrients—especially amino acids—is therefore high compared to other tissues, leaving the hematopoietic tissue sensitive to malnutrition [9]. Certainly, anemia associated with protein-energy malnutrition is relatively common in children and elderly people in general [10]. The constant production of blood cells from hematopoietic stem cells (HSC) is also influenced by the latter’s microenvironment, a complex biological niche [11]. In recent years, interest has grown in understanding the influence of diet on the physiology and viability of HSC. Several studies, particularly those investigating the pretransplant conditioning of the bone marrow, have shown the influence exerted by dietary BCAAs and cysteine (Cys) on the function of HSC and their microenvironment. Indeed, Val and Cys have been reported indispensable for the maintenance of HSC [12]. In vitro, neither human nor rat HSC can proliferate in media without these amino acids, and rats fed a Val-restricted diet show a reduced HSC count within a week [12].

Table 3 Analysis of plasma amino acid plasma levels and dietary practices (natural protein and special amino acid mixture intake) according to ferritin levels using multilevel linear regression

|                        | Regression coefficient (95% CI) | p value |
|------------------------|---------------------------------|---------|
| Natural protein intake (g/kg/day) | $-72.1 \ (-119.6; -24.5)$ | 0.003   |
| Special mixture of precursor-free amino acids intake (g/kg/day) | 37.8 (6.1; 69.5) | 0.019   |
| Valine (µmol/L) | $-8.6 \ (-12.3; -4.8)$ | < 0.001 |
| Isoleucine (µmol/L) | $-5.2 \ (-12; 1.5)$ | 0.128   |
| Leucine (µmol/L) | 5.6 (2.2; 9.1) | 0.001   |
| Valine/Leucine | $-771.5 \ (-987.4; -555.5)$ | < 0.001 |
| Isoleucine/Leucine | $-431 \ (-788.6; -73.3)$ | 0.018   |

Fig. 1 Correlation between natural protein intake, SMAA consumption and plasma BCAA with respect to plasma ferritin. Scatter plot with the values of the 10 patients; the red lines represent the predictions of the multilevel model. Val: Valine; Ile: Isoleucine; Leu: Leucine
study that examined the effect of BCAA balance on HSC viability, restricting the Val intake by 10% led to a significant fall in HSC numbers. The same 10% restriction in Val in the presence of increased Ile and Leu led to the complete blockage of HSC proliferation [13]. The reason why HSC are so sensitive to a reduced Val intake and to disequilibrium between BCAAs has not been explored. However, it may involve Val's role as a structural unit of proteins, or some relationship with cell signaling [11].

The above evidence suggests that an imbalance of the BCAA can have a negative effect on the bone marrow. Certainly, among the present patients, reduced plasma Val negatively correlated with ferritin levels, whereas Leu was directly associated with iron overload. Moreover, there was an inverse relation between the ratios Val/Leu and Ile/Leu with plasma ferritin.

The dietary recommendations for PA patients are based on the restriction of natural protein intake, the use of SMAA together with the avoidance of prolonged fasting and adequate energy supply [2]. The SMAA contains no Val, Ile, Met and Thr, but a normal-high Leu levels and they are recommended if natural protein tolerance is below FAO/WHO/UNU safe levels [2]. The actual amount of medical food versus intact protein intakes are not detailed by the current guidelines and protein tolerance should be titrated individually [2, 14].

Thus, in PA patients, the combination between the natural protein restriction and the use of SMAA might result in an imbalanced BCAA dietary content with high Leu/Val or Leu/Ile ratios [15] that will directly reflect in BCAA plasma levels [16, 17], since these are essential amino acid entirely provided by the diet. Still, there are scarce studies investigating the impact of an BCAA imbalanced diet in organic aciduria patients. In an observational study in methyl malonic acidemia patients, increased leucine intake was associated with adverse growth outcomes [16].

In mice, elevated Leu was found to reduce plasma Val and Ile via system L amino acid transporter [18]. Animals fed high doses of Leu show low central nervous system concentrations of tryptophan, Val, Ile, Met and alanine, which might affect the synthesis of neurotransmitters [19]. Other authors have reported the importance of BCAA equilibrium in body growth and cellular immunity in animal models [20, 21]. In normal adults, high Leu intake was found to increase ammonia levels and to significantly decrease plasma concentration of Val and Ile [22].

The present work is the first to provide positive evidence of a nutritional component underlying the hematological complications of PA during stable metabolic periods. Our findings suggest that the natural protein and medical food intake as well as the balance of BCAA plasma levels might play an important role in the onset and development of severe anemia in PA. The natural protein restriction below 25–30% of total protein intake together with generous use of medical food might result in branched-chain amino acids imbalance and should be avoided.

The small number of patients examined is an important limitation of this study. Confirmatory studies involving international registries should be performed.

**Conclusion**

Patients with PA can experience serious hematological complications even during periods of metabolic stability. The severe anemia may be due to an imbalance of BCAA plasma levels, presumably due to a low natural protein intake/high synthetic protein consumption. Further work is needed to confirm the importance of dietary practices and the BCAA equilibrium in the development of long-term hematological complications in patients with PA.

**Abbreviations**

PA: Propionic academia; BCAA: Branched-chain amino acids; Val: Valine; Ile: Isoleucine; Leu: Leucine; Met: Methionine; Thr: Threonine; OLCFAs: Odd-numbered long-chain fatty acids; SMAA: Special mixture of precursor-free amino acids; NPI: Natural protein intake.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13023-021-01865-7.

**Additional file 1.** Descriptive analysis of plasma branched-chain amino acids levels. Val: valine; Ile: isoleucine; Leu: Leucine.

**Additional file 2.** Excel data.

**Acknowledgements**

Not applicable.

**Authors’ contributions**

SS had a significant contribution to the conception and design of the study. ABQ, MMP and FA contributed to the acquisition and interpretation of the data. BMFF performed the statistical analysis. VQ and MSM analyzed the anemia hematological markers. PA carried out the ion-exchange chromatography. All authors read and approved the final manuscript.

**Funding**

This work was supported by the “Ramon Areces’ Foundation (Grant Number C1/P17A2827).

**Availability of data and materials**

All data generated or analyzed during this study are included in this published article and its supplementary information files.
Declarations

Ethical approval and Consent to participate
The study was approved by the Ethical Committee of our hospital (Hospital Universitario Ramon y Cajal, Madrid, Spain). Patients or their parents signed an informed consent prior to the inclusion in the study.

Consent for publication
Informed consent to participate in the study was obtained from participants or their parent or legal guardian in the case of children under 16.

Competing interests
SS has received travel and speaker fees from Nutricia, Mead Johnson, Genzyme, Recordatti Rare Diseases, Vitafo-Nestlé, BioMarin. ABQ has received travel and speaker fees from Nutricia, Mead Johnson, Genzyme, Recordatti Rare Diseases, Vitafo-Nestlé, Takeda, BioMarin; advisory fees from BioMarin and Merk Serono. BMFF declares that she has no conflict of interest. VQ declares that he has no conflict of interest. PA has received travel and speaker fees from Nutricia, Mead Johnson, Genzyme, Recordatti Rare Diseases, Vitafo-Nestlé, BioMarin. PA declares that she has no conflict of interest. MSM declares that she has no conflict of interest. MMP has received travel and speaker fees from Nutricia, Mead Johnson, Genzyme, Recordatti Rare Diseases, Vitafo-Nestlé, Takeda, BioMarin.

Author details
1 Servicio de Pediatría, Unidad de Enfermedades Metabólicas, Hospital Universitario Ramón y Cajal, IRYCIS, Crta de Colmenar Viejo, km 9,100, 28034 Madrid, Spain. 2 Unidad de Bioestadística Clínica, Instituto Ramon y Cajal de Investigación Sanitaria, CIBER Epidemiología y Salud Pública (CIBERESP), Hospital Universitario Ramón y Cajal, Crta de Colmenar Viejo, km 9,100, 28034 Madrid, Spain. 3 Unidad de Enfermedades Metabólicas, Hospital Universitario Ramón y Cajal, IRYCIS, Crta de Colmenar Viejo, km 9,100, 28034 Madrid, Spain. 4 Unidad de Oncohematología, Servicio de Pediatría, Hospital Universitario Ramón y Cajal, IRYCIS, Crta de Colmenar Viejo, km 9,100, 28034 Madrid, Spain. 5 Centro de Diagnóstico de Enfermedades Moleculares, Centro de Biología Molecular, Universidad Autónoma de Madrid, CIBERER, IdiPAZ, C/ Francisco Tomás y Valiente, 7, 28049 Madrid, Spain.

Received: 20 January 2021 Accepted: 10 May 2021 Published online: 18 May 2021

References
1. Wongkittichote P, Ah Mew N, Chapman KA. Propionyl-CoA carboxylase—a review. Mol Genet Metab. 2017;122:145–52.
2. Baumgartner MR, Hörster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2019;14:910.
3. Haijes HA, Jans JJM, Tas SY, Verhoeven-Duif NM, van Hasselt PM. Pathophysiology of propionic and methylmalonic acidemias. Part 1: complications. J Inherit Metab Dis. 2019;42:730–44.
4. Haijes HA, van Hasselt PM, Jans JJM, Verhoeven-Duif NM, Palascak E, Nijhuis CM. Treatment strategies. J Inherit Metab Dis. 2019;42(5):745–61.
5. StataCorp. Stata statistical software: release 16. College Station: StataCorp LLC. 2019.
6. Kölker S, Valayannopolos V, Burlina AB, et al. The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype. J Inherit Metab Dis. 2015;38:1059–74.
7. Stork LC, Ambruso DR, Wallner SF, Sambrano JE, Moscinski LC, Wilson HL, McCabe ER. Pancytopenia in propionic acidemia: hematologic evaluation and studies of hematopoiesis in vitro. Pediatr Res. 1986;20:783–8.
8. Inoue S, Krieger I, Sarnaik A, Ravindranath Y, Fracassa M, Ottenbreit MJ. Inhibition of bone marrow stem cell growth in vitro by methylmalonic acid: a mechanism for pancytopenia in a patient with methylmalonic acidemia. Pediatr Res. 1981;15:95–8.
9. Santos EW, Oliveira DC, Silva GB, Tsujita M, Beltran JO, Hastea A, Fock RA, Borelli P. Hematological alterations in protein malnutrition. Nutr Rev. 2017;75:909–19.
10. Bianchi VE. Role of nutrition on anemia in elderly. Clin Nutr ESPEN. 2016;11:e1–11.
11. Wilkinson AC, Yamazaki S. The hematopoietic stem cell diet. Int J Hematol. 2018;107:634–41.
12. Taya Y, Ota Y, Wilkinson AC, Kanazawa A, Watarai H, Kasa M, Nakauchi H, Yamazaki S. Depleting dietary valine permits nonmyeloablative mouse hematopoietic stem cell transplantation. Science. 2016;354:1152–5.
13. Wilkinson AC, Morita M, Nakauchi H, Yamazaki S. Branched-chain amino acid depletion conditions bone marrow for hematopoietic stem cell transplantation avoiding amino acid imbalance-associated toxicity. Exp Hematol. 2018;63:12–16.e1.
14. Forny P, Hörster F, Ballhausen D, Chakrapani A, Chapman KA, Dionisi-Vici C, Díaz M, Grünert SC, Grunevald S, Hallilou G, Hochuli M, Honzik T, Karall D, Martinelli D, Molena F, Sass JO, Scholl-Bürge S, Tal G, Williams M, Huemer M, Baumgartner MR. Guidelines for the diagnosis and management of methylmalonic acidemia and propionic acidemia: first revision. J Inherit Metab Dis. 2021. https://doi.org/10.1002/jimd.12370.
15. Myles JG, Manoli I, Venditti CP. Effects of medical food leucine content in the management of methylmalonic and propionic acidemias. Curr Opin Clin Nutr Metab Care. 2018;21:142–8.
16. Manoli I, Myles JG, Sloan JL, Shchelochkov OA, Venditti CP. A critical reappraisal of dietary practices in methylmalonic acidemia raises concerns about the safety of medical foods. Part 1: isolated methylmalonic acidemias. Genet Med. 2016;18(4):386–95.
17. Molena F, Gleich F, Burgard P, van der Poel AG, Summar ML, Chapman KA, Barić I, Lund AM, Kölker S, Williams M. Additional individual contributors from E-IMD. Evaluation of dietary treatment and amino acid supplementation in organic acidurias and urea-cycle disorders: on the basis of information from a European multicenter registry. J Inherit Metab Dis. 2019;42(6):1162–75.
18. Zhen H, Nakamura K, Kitaura Y, Kadota Y, Ishikawa T, Kondo Y, Xu M, Shimomura Y. Regulation of the plasma amino acid profile by leucine via the system L amino acid transporter. Biosci Biotechnol Biochem. 2015;79:2057–62.
19. Wessels AG, Kluge H, Hinche F, Kioowski A, Shukowskoi A, Corrent E, Bartelt J, Köning B, Stangl G. High leucine diets stimulate cerebral branched-chain amino acid degradation and modify serotonin and ketone body concentrations in a pig model. Proc ONE. 2016;11:e0150376.
20. Gatnau R, Zimmerman DR, Nissen SL, Wannemuehler M, Ewcan RC. Effects of excess dietary leucine and leucine catabolites on growth and immune responses in weaning pigs. Anim Sci. 1995;73:159–65.
21. Imamura W, Yoshimura R, Takai M, Yamamura J, Kanamoto R, Kato H. Adverse effects of excessive leucine intake depend on dietary protein intake: a transcriptomic analysis to identify useful biomarkers. J Nutr Sci Vitaminol (Tokyo). 2013;59:495–55.
22. Elango R, Chapman K, Rafii M, Ball RO, Pencharz PB. Determination of the tolerable upper intake level of leucine in acute dietary studies in young men. Am J Clin Nutr. 2012;96(4):759–67.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.